<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000659</url>
  </required_header>
  <id_info>
    <org_study_id>IDE 1006</org_study_id>
    <nct_id>NCT04000659</nct_id>
  </id_info>
  <brief_title>Episealer® Knee System IDE Clinical Study</brief_title>
  <official_title>A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Effectiveness of the Episealer® Knee System Compared to Microfracture for the Treatment of Focal Femoral Knee Chondral or Osteochondral Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Episurf Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MCRA, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Episurf Medical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized, prospective, multicenter, controlled clinical trial of the&#xD;
      Episealer Knee System.The Episealer Knee System is intended for subjects with a focal femoral&#xD;
      knee chondral or osteochondral lesion that is causing pain and/or disability and requires&#xD;
      surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and clinical effectiveness of&#xD;
      the Episealer Knee System (Episealer Trochlea Solo, Episealer Femoral Twin, and Episealer&#xD;
      Condyle Solo) compared to microfracture (with or without debridement) in a group of subjects&#xD;
      that require repair of up to 2 focal femoral chondral or osteochondral lesions in the knee.&#xD;
&#xD;
      Clinical success will be analyzed via subject reported outcomes to measure function and pain&#xD;
      improvements as compared to baseline, incidence of secondary surgical interventions for the&#xD;
      treated knee, absence of subsidence or migration through radiographic assessment, and&#xD;
      assessment of weight-bearing status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 180 subjects will be enrolled and randomized using a 2:1 ratio (Episealer: Microfracture). Within each site, subjects will be randomized into one of the two study arms using a blocked randomization scheme with varying block sizes.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>In this investigation, neither the investigator nor the subject can be blinded to the treatment group assignment due to the implant's distinctive form that can be detected on radiographs; however, the randomization assignment will not be disclosed to the subject until after surgery is performed.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Knee Injury &amp; Osteoarthritis Outcome Score (KOOS) Subscores</measure>
    <time_frame>24 Months</time_frame>
    <description>This endpoint will examine the change in KOOS subscores at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Analog Scale (VAS) Pain Scores</measure>
    <time_frame>24 Months</time_frame>
    <description>This endpoint will examine the change in VAS Pain scores at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Secondary Surgical Intervention</measure>
    <time_frame>24 Months</time_frame>
    <description>This endpoint will examine the incidence of Secondary Surgical Interventions (SSIs) at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of subsidence or migration at 24 months</measure>
    <time_frame>24 Months</time_frame>
    <description>This endpoint will examine the incidence of subsidence/migration at 24 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight bearing status</measure>
    <time_frame>8 weeks</time_frame>
    <description>This endpoint will examine the weight bearing status at 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the KOOS Subscores at all follow-up time points</measure>
    <time_frame>3-weeks, 8-weeks, 6-months, 12-months, and 24-months</time_frame>
    <description>This endpoint will examine the change in KOOS subscores at all follow-up time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VAS Pain score at all follow-up time points</measure>
    <time_frame>3-weeks, 8-weeks, 6-months, 12-months, and 24-months</time_frame>
    <description>This endpoint will examine the change in VAS Pain scores at all follow-up time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 12-Item Short Form Survey (SF-12) score at all follow-up time points</measure>
    <time_frame>3-weeks, 8-weeks, 6-months, 12-months, and 24-months</time_frame>
    <description>This endpoint will examine the change in SF-12 scores at all follow-up time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of radiographic findings at all follow-up time points</measure>
    <time_frame>8 weeks, 12-months, and 24-months</time_frame>
    <description>This endpoint will examine the incidence of radiographic findings at all follow-up time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and device deficiencies at all follow-up time points</measure>
    <time_frame>3-weeks, 8-weeks, 6-months, 12-months and 24-months</time_frame>
    <description>This endpoint will examine the safety via the incidence of adverse events and device deficiencies at all follow-up time points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Degenerative Lesion of Articular Cartilage of Knee</condition>
  <arm_group>
    <arm_group_label>Episealer Knee System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control arm will comprise of subjects that will receive a Microfracture surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Episealer Knee System</intervention_name>
    <description>The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.</description>
    <arm_group_label>Episealer Knee System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.</description>
    <arm_group_label>Microfracture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age between 30 and 70 years&#xD;
&#xD;
          -  Have up to 2 symptomatic femoral chondral or osteochondral defects in the index knee&#xD;
             on the medial or lateral femoral condyles or the knee trochlea area&#xD;
&#xD;
          -  Have undergone prior non-surgical management in the index knee&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Have a BMI greater than 35 kg/m2&#xD;
&#xD;
          -  Have undergone prior surgical treatment for the cartilage defect&#xD;
&#xD;
          -  Have an existing knee prosthesis in the index knee&#xD;
&#xD;
          -  Have a bone disease that impacts bone quality&#xD;
&#xD;
          -  Have rheumatoid arthritis&#xD;
&#xD;
          -  Have a known immunodeficiency&#xD;
&#xD;
          -  Have known allergies to Cobalt-Chrome alloy or Titanium&#xD;
&#xD;
          -  Have any contraindication to MRI&#xD;
&#xD;
          -  Any condition, therapy or medication that would interfere with healing or the&#xD;
             evaluation of outcome measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarina Flodström</last_name>
    <role>Study Director</role>
    <affiliation>Episurf Medical Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarina Flodström</last_name>
    <phone>1 686 845 9447</phone>
    <email>Katarina.Flodstrom@episurf.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Physicians Research Group</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vianeth Santiago</last_name>
      <phone>480-868-7014</phone>
      <email>v.santiago@prgresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Tammy Fuentes</last_name>
      <phone>800-774-1534</phone>
      <email>t.fuentes@prgresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Eifler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Sports Medicine Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Maggio</last_name>
      <phone>504-842-0263</phone>
      <email>jmaggio@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Graylin Jacobs</last_name>
      <phone>(504) 842-0263</phone>
      <email>Graylin.jacobs@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Deryk Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Williams</last_name>
      <phone>551-996-4261</phone>
      <email>Rose.Williams@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Yair Kissin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plancher Orthopaedics &amp; Sports Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Petterson</last_name>
      <phone>203-869-2002</phone>
      <email>spetterson@ofals.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Plancher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna DeFranco, BS</last_name>
      <phone>614-293-2761</phone>
      <email>Jenna.DeFranco@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David Flanigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Evans, BS</last_name>
      <phone>731-803-4464</phone>
      <email>mevans@crssites.com</email>
    </contact>
    <investigator>
      <last_name>Jason Hutchison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Idrætsklinikken, Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsten Grønbech Nielsen</last_name>
      <phone>+45 40491184</phone>
      <email>torsten.gronbech.nielsen@auh.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Martin Lind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Berlin Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derya Belkacem</last_name>
      <phone>030/450 615 196</phone>
      <email>derya.belkacem@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Anne Zergiebel</last_name>
      <phone>030/450 515 235</phone>
      <email>anne.zergiebel@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Jung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthocentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Kaiser</last_name>
      <phone>+4940443639</phone>
      <email>kaiser@oc-h.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Holt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry and Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerri McGowan</last_name>
      <email>kerri.mcgowan@uhcw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Feisal Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>So16 6yd</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Beveridge</last_name>
      <phone>+442381208141</phone>
      <email>michelle.beveridge@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Frame, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Orthopaedic Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B31 2AP - UK</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudette Jones, RN</last_name>
      <email>claudette.jones@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tanweer Ashraf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Jones &amp; Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH)</name>
      <address>
        <city>Oswestry</city>
        <zip>Shropshire SY10 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Denton</last_name>
      <email>jeandenton@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paul Jermin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee</keyword>
  <keyword>Cartilage</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

